屈昔多巴治疗体位性低血压研究进展

The Research Progress of Droxidopa in the Treatment of Orthostatic Hypotension

体位性低血压(OH)在老年人群中的发病率随年龄增长呈升高趋势,可增加心血管事件和跌倒的风险。其病因可分为原发性和继发性。典型症状包括头昏、视物模糊、乏力甚至晕厥等。诊断上需通过症状及病史筛查后进行详细体格检查、测量血压等,确诊后选择合适的治疗方式。屈昔多巴作为一种合成的儿茶酚胺,是2014年美国食品药品管理局批准用于该病的新药。该文就体位性低血压的诊治进展及屈昔多巴在治疗中的作用进行综述。

The incidence of orthostatic hypotension （OH） in the elderly adults is increased with age, which can incre0se the risk of cardiovascular events and fall. The etiology can be divided into primary and secondary. The typical symptoms include dizziness, blurred vision, fatigue and even syncope, etc. We should first screen by symptoms and medical history, and then make the diagnosis after detailed physical examination and blood pressure measurement, and choose the appropriate treatment after diagnosis. Drexidopa is a kind of synthetic catecholamine, which is a new drug for this disease approved by the FDA in 2014. Here is to make a review of the progress of the diagnosis and treatment of orthostatic hypotension and the role of droxidopa in the treatment.